Skip to main content
OpenTrials
Completed

NCT Number: NCT03194256

Evaluating New Nicotine Standards for Cigarettes - Project 3

This study is designed to examine how the nicotine content of cigarettes and the nicotine concentration and flavors in e-liquids influence responses to and use of these products in adolescent smokers. Participants will complete a total of six sessions (an in-person screening/baseline session and five lab sessions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year–20 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brown University School of Public Health

Providence, Rhode Island, 02912, United States

About this study

Adolescence is a critical developmental period for tobacco initiation and progression to regular use and dependence. The Food and Drug Administration (FDA) has the authority to establish standards for tobacco products for the protection of public health, including the authority to mandate a reduction in the nicotine content of all cigarettes to minimally addictive levels. Numerous studies have found that adult smokers who are switched to very low nicotine content (VLNC) cigarettes experience reductions in smoking rates, nicotine intake, nicotine dependence and abstinence-induced craving relative to those who use normal nicotine content (NNC) cigarettes. However, studies of VLNC cigarettes in adolescent smokers are limited and more information is needed to inform potential product standards. Furthermore, use of electronic nicotine delivery systems (ENDS), e-cigarettes or vaping devices, has increased dramatically in adolescents. Therefore, effects of VLNC cigarettes on smoking in youth should be examined in the context of vaping device availability. This study is designed to examine how the nicotine content of cigarettes and the nicotine concentration and flavors in e-liquids influence responses to these products in adolescents.

Participants will complete an in-person baseline session in which eligibility criteria are confirmed and background questionnaires are completed. Next, participants will complete five in-person lab sessions in which NNC or VLNC cigarettes are available (based on random assignment). During the first lab session, participants will test the assigned research cigarettes when no alternative product is available. During each of the four remaining lab sessions, smokers' responses to the assigned research cigarettes will be compared to their responses to a vaping device with the following characteristics: 1) no nicotine, tobacco flavor; 2) no nicotine, non-tobacco flavor; 3) moderate nicotine concentration, tobacco flavor; or 4) moderate nicotine concentration, non-tobacco flavor. In each session, after sampling and rating the subjective effects of the products available during that session, participants will make a series of 10 choices. Choices will be for either 2 puffs of the research cigarette, 2 puffs of the vaping device, or abstinence from puffing.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 15-20
  • Adolescents who report current daily or near daily cigarette smoking for at least 3 months
  • Must have used an electronic nicotine device on a minimum of two lifetime occasions.
  • Breath Carbon Monoxide (CO) levels > 5 ppm (if < 5 ppm, then cotinine assay via NicAlert Strip = > 3)
  • Speak, comprehend, and read English well enough to complete study procedures

Exclusion criteria

  • Unwilling to use research cigarettes or ENDS as part of the study
  • Intention to quit smoking in the next 30 days
  • Using tobacco products (other than ENDS or roll-your-own tobacco) > 15 days in the past 30 days.
  • Any medical or psychiatric condition in which participation is likely to post a significant threat to health or for which the condition could interfere with the ability of the participant to fully participants (as determined by the LMP)
  • Self-reported illicit use of any drug except marijuana > 10 days in the past 30 days
  • Binge drinking alcohol (>10 days in the past 30 days, >4/5 drinks in a 2-hour period (female/male))
  • Pregnant or breastfeeding
  • CO reading > 80 ppm
  • Systolic BP outside the range of 90-159, diastolic BP outside the range of 50-99, or heart rate outside the range of 45-104. Participants failing for any of these criteria will be allowed to re-screen once per criterion.
  • Indicating Yes on Questions 4-6 on the MINI with a suicide attempt in the past 2 years (if within the past 2-10 years, LMP approval required).
  • Having participated in another research study during the past year in which they were switched to reduced nicotine cigarettes for longer than one week.

Treatment and study plan

Spectrum Research Cigarettes

Behavioral

Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.

Primary outcomes

  1. Number of Cigarette Puffs Taken (0 to 20)

    Time frame: 30-minute preference task

    The number of cigarette puffs selected during a 30 minute choice procedure when no vaping device was available

  2. Number of Cigarette Puffs Taken (0 to 20) When the Available Vaping Device Has 3mg/ml of Nicotine and Was Available in Tobacco Flavor

    Time frame: 30-minute preference task

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device has 3mg/ml of nicotine and was available in tobacco flavor

  3. Number of Cigarette Puffs Taken (0 to 20) When the Available Vaping Device Has 3mg/ml of Nicotine and Was Available in Non-tobacco Flavors

    Time frame: 30-minute preference task

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device has 3mg/ml of nicotine and was available in non-tobacco flavors

  4. Number of Cigarette Puffs Taken (0 to 20) When the Available Vaping Device Has 18mg/ml of Nicotine and Was Available in Tobacco Flavor

    Time frame: 30-minute preference task

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device has 18mg/ml of nicotine and was available in tobacco flavor

  5. Number of Cigarette Puffs Taken (0 to 20) When the Available Vaping Device Has 18mg/ml of Nicotine and Was Available in Non-tobacco Flavors

    Time frame: 30-minute preference task

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device has 18mg/ml of nicotine and was available in non-tobacco flavors

Secondary outcomes

  1. Number of E-cig Puffs Taken (0 to 20) When the Available Vaping Device Contained 3mg/ml Nicotine and Was Available in Tobacco Flavor

    Time frame: 30-minute preference task session

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device contained 3mg/ml nicotine and was available in tobacco flavor

  2. Number of E-cig Puffs Taken (0 to 20) When the Available Vaping Device Contained 3mg/ml Nicotine and Was Available in Non-tobacco Flavors

    Time frame: 30-minute preference task session

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device contained 3mg/ml nicotine and was available in non-tobacco flavors

  3. Number of E-cig Puffs Taken (0 to 20) When the Available Vaping Device Contained 18mg/ml Nicotine and Was Available in Tobacco Flavor

    Time frame: 30-minute preference task session

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device contained 18mg/ml nicotine and was available in tobacco flavor

  4. Number of E-cig Puffs Taken (0 to 20) When the Available Vaping Device Contained 18mg/ml Nicotine and Was Available in Non-tobacco Flavors

    Time frame: 30-minute preference task session

    The number of cigarette puffs selected during a 30 minute choice procedure when the available vaping device contained 18mg/ml nicotine and was available in non-tobacco flavors

  5. Carbon Monoxide Change From pre-to the Post-choice Task When no Vaping Device Was Available

    Time frame: 30-minute preference task

    Post-choice CO minus pre-choice CO at session 1 in which no vaping device was available

  6. Carbon Monoxide Change From pre-to the Post-choice Task When the Available Vaping Device Contained 3mg/ml Nicotine and Was Available in Tobacco Flavor

    Time frame: 30-minute preference task

    Post-choice CO minus pre-choice CO when the available vaping device contained 3mg/ml nicotine and was available in tobacco flavor

  7. Carbon Monoxide Change From pre-to the Post-choice Taskwhen the Available Vaping Device Contained 3mg/ml Nicotine and Was Available in Non-tobacco Flavors

    Time frame: 30-minute preference task

    Post-choice CO minus pre-choice CO when the available vaping device contained 3mg/ml nicotine and was available in non-tobacco flavors

  8. Carbon Monoxide Change From pre-to the Post-choice Task When the Available Vaping Device Contained 18mg/ml Nicotine and Was Available in Tobacco Flavor

    Time frame: 30-minute preference task

    Post-choice CO minus pre-choice CO when the available vaping device contained 18mg/ml nicotine and was available in tobacco flavor

  9. Carbon Monoxide Change From pre-to the Post-choice Task When the Available Vaping Device Contained 18mg/ml Nicotine and Was Available in Non-tobacco Flavors

    Time frame: 30-minute preference task

    Post-choice CO minus pre-choice CO when the available vaping device contained 18mg/ml nicotine and was available in non-tobacco flavors

Other outcomes

  1. Number of Choices for Cigarette Puffs

    Time frame: 30-minute preference task at each of the 5 laboratory sessions

    0 to 10

  2. Number of Choices for E-cig Puffs

    Time frame: 30-minute preference task at each of the 5 laboratory sessions

    0 to 10

  3. Number of Choices to Abstain From Puffing

    Time frame: 30-minute preference task at each of the 5 laboratory sessions

    0 to 10

  4. Drop-out Rate

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures of compliance

  5. Minnesota Nicotine Withdrawal Scale (MNWS)

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures withdrawal symptoms

  6. Questionnaire of Smoking Urges (QSU)

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures craving

  7. Positive and Negative Affect Scale (PANAS)

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures positive and negative affect

  8. Cigarette Evaluation Scale (CES)

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures subjective responses cigarettes

  9. Cigarette Purchase Task

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures demand for cigarettes across a range of prices

  10. Perceived Health Risk Scale

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures perceived risk of cigarettes

  11. Heart Rate

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures of cardiovascular function

  12. Blood Pressure

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Measures of cardiovascular function

  13. Total Nicotine Equivalents (TNE)

    Time frame: Baseline; Week 1

    Biomarkers

  14. Nicotine Metabolite Ratio (NMR)

    Time frame: Baseline; Week 1

    Biomarkers

  15. Cotinine

    Time frame: Baseline; Week 1

    Biomarkers: measures a metabolite of nicotine

  16. Carbon Monoxide (CO)

    Time frame: Baseline-Lab Session 5; 2-8 weeks; average 3-4 weeks

    Biomarkers: measures expired alveolar carbon monoxide level

Sponsors and collaborators

Lead sponsor

Brown University

Other

Collaborators

  • Food and Drug Administration (FDA)
  • National Institute on Drug Abuse (NIDA)
  • University of Minnesota
  • Wake Forest University

Registry information

Official study title

Effects of Very Low Nicotine Content Cigarettes and E-cigarette Characteristics on Smoking in Adolescents

Acronym: CENIC2-P3

Important dates

Study start
2018
Primary completion
2022
Study completion
2022
First posted
Jun 21, 2017
Registry last updated
Dec 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.